Analgesia Comparison of Nalbuphine and Morphine for Laparoscopic Myomectomy

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03288428

Enrollment

Registered

2017-09-20

Start date

2017-05-01

Completion date

2018-12-31

Last updated

2026-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

to compare the analgesia and side effect of nalbuphine and morphine for elective Laparoscopic myomectomy.

Detailed description

To compare the analgesia and side effect of nalbuphine and morphine for elective Laparoscopic myomectomy, by using patient controlled analgesia postoperatively, a randomized, double blind clinical trial. Patients undergoing elective Laparoscopic myomectomy are randomly divided into two groups: nalbuphine and morphine groups. All patients are under general anesthesia with routine methods. The nalbuphine group receive postoperative patient controlled analgesia using nalbuphine 30mg/120ml, while the morphine group receive postoperative patient controlled analgesia using morphine 60mg/120ml. Perioperative parameters are to be collected to compare the two groups.

Interventions

DRUGNalbuphine

patient controlled analgesia with Nalbuphine

DRUGMorphine

patient controlled analgesia with Morphine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Masking description

double blind

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* elective Laparoscopic myomectomy patients 24hr post-operative patient controlled analgesia analgesia no mild or severe liver or renal disfunction

Exclusion criteria

* can't understand patient controlled analgesia device refuse trial

Design outcomes

Primary

Measure	Time frame	Description
numerical rating scale	24 hr post-operatively	1-10

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 20, 2026